Skip to content

Neil W Bailey

3 papers in the library · 11 citations · publishing 2022-2025

Papers

Meditators probably show increased behaviour-monitoring related neural activity

bioRxiv Preprint Server July 7, 2022 Neil W Bailey, Harry Geddes, Isabella Zannettino et al. 5 citations preprint

Experienced meditators exhibit distinct neural activity during performance monitoring and error-processing compared to non-meditators. Using a larger sample and more rigorous analyses than prior work, the study clarifies previously inconsistent findings, showing that long-term mindfulness practice is associated with altered brain responses when detecting and processing errors.

Experienced meditators show greater forward traveling cortical alpha wave strengths.

Annals of the New York Academy of Sciences July 2, 2025 Neil W Bailey, Aron T Hill, Kate Godfrey et al. 4 citations

Mindfulness meditation, which trains attention on sensory experiences with nonjudgmental awareness, is thought to sharpen sensory processing and reduce top-down expectations. This study measured forward and backward traveling cortical alpha waves—proposed to reflect bottom-up inhibition and top-down inhibition, respectively—using electroencephalography in meditators and nonmeditators. During eyes-closed resting (97 participants) and a visual Go/No-go task (126 participants), meditators showed stronger forward traveling waves than nonmeditators in both conditions, and weaker backward traveling waves during rest. These neural differences may underlie enhanced attention and reduced mind-wandering associated with meditation, supporting models where mental training increases sensory awareness.

Ketamine in psychiatry: Ethical imperatives in harnessing a controversial yet promising therapy

Australian & New Zealand Journal of Psychiatry December 11, 2025 Adem T Can, Jim Lagopoulos, Paul B Fitzgerald et al. 2 citations

Ketamine is a fast-acting treatment for psychiatric conditions that do not respond to other therapies, but its use is controversial. Evidence shows it can reduce depression, anxiety, and suicidal thoughts, yet it also carries risks such as dissociation, dependence, and unknown long-term effects. Its reputation as a recreational drug adds stigma and regulatory hurdles. The authors argue that ketamine should be accepted as a legitimate psychiatric treatment, but its use must be guided by ethical principles—autonomy, beneficence, non-maleficence, and justice—and supported by careful regulation and research, avoiding both unwarranted rejection and premature hype.